Correspondence 0001193125-24-019400 from Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc.
Date: Jan. 30, 2024 · CIK: 0001999480 · Accession: 0001193125-24-019400
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276495
Letter
January 30, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Lauren Hamill, Tim Buchmiller, Li Xiao, Mary Mast
Re: Alto Neuroscience, Inc.
Registration Statement on Form S-1, as amended
File No. 333-276495
Acceleration Request
Requested Date: Thursday, February 1, 2024
Requested Time: 4:30 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Alto Neuroscience, Inc. (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:30 P.M., Eastern Time, on February 1, 2024, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
JEFFERIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 30, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill, Tim Buchmiller, Li Xiao, Mary Mast Re: Alto Neuroscience, Inc. Registration Statement on Form S-1, as amended File No. 333-276495 Acceleration Request Requested Date: Thursday, February 1, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Alto Neuroscience, Inc. (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:30 P.M., Eastern Time, on February 1, 2024, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, JEFFERIES LLC COWEN & COMPANY, LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As representatives of the underwriters JEFFERIES LLC By: /s/ Michael Brinkman Name: Michael Brinkman Title: Managing Director & Joint U.S. Head of Biopharmaceuticals COWEN & COMPANY, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Nick Oust Name: Nick Oust Title: Managing Director [Signature Page to Underwriters’ Acceleration Request]